Goodwin Procter advised Avalyn Pharma Inc., and Wilson Sonsini Goodrich & Rosati has advised SR One and Novo Holdings on the transaction. Avalyn Pharma Inc., a...
Avalyn Pharma Closes $100 Million Oversubscribed Series D Financing
Rapport Therapeutics’ $150 Million Series B Funding Round
Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
Rapport Therapeutics’ $100 Million Series A Financing
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
Alnylam Pharmaceuticals’ $1.035 Billion Notes Offering
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...
SpringWorks Therapeutics’ $300 Million Shares Private Placement
Goodwin Procter advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its private placement transaction with a select group of institutional investors to issue...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Asher Biotherapeutics’ $108 Million Series B Financing
Goodwin Procter advised Asher Biotherapeutics on the deal. Asher Biotherapeutics announced the closing of its Series B financing, which raised $108 million. The financing was led by...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....